Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited – Exploring the “Space”
Cancer Letters · 2025-07 · 622 · 217699
DOI: 10.1016/j.canlet.2025.217699 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025-07. Verfasst von Konstantin Bräutigam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Research, Centre for Evolution and Cancer, London, SM2 5NG, United Kingdom; Institute of Tissue Medicine and Pathology, Universit…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Carcinoma, Pancreatic Ductal, Lymphocytes, Tumor-Infiltrating, Pancreatic Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most deadly malignancies with a highly immunosuppressive tumor immune microenvironment (TIME) that hinders effective therapy. PDAC is characterized by significant heterogeneity in immune cell composition, spatial distribution and activation states, which impacts tumor progression and treatment response. Tumour-infiltrating lymphocytes (TILs), including CD4+ T-helper cells, CD8+ cytotoxic T-cells and FOXP3+ regulatory T-cells, play a key role in immune regulation, yet PDAC is largely an immunologically "cold" tumour with limited effector T-cell infiltration. The surrounding cellular microenvironment, particularly Cancer Associated Fibroblasts (CAFs) and macrophages, contributes to immune evasion by promoting a fibrotic and desmoplastic barrier that limits TIL infiltration. The prognostic significance of TILs is increasingly recognized, with higher densities correlating with improved survival, whereas regulatory T-cell infiltration and immunosuppressive stromal interactions are associated with poor outcomes. Emerging therapeutic strategies targeting the TIME (e.g., CAFs), immune checkpoint inhibitors, and TIL-based therapies offer the potential to overcome resistance. Future research must focus on optimizing immunotherapy strategies and unravelling the complex stromal-immune interactions to improve clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Cancer Research, Centre for Evolution and Cancer, London, SM2 5NG, United Kingdom; Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland. Electronic address: konstantin.braeutiga…
- Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria; Institute of Biomedical Sciences, Medical Faculty of Medicine, University of Maribor, Maribor, Slovenia.
- Department of Pathomorphology, Jagiellonian University Medical College, Krakow, Poland.
- Department of Pathology, Rigshospitalet, DK 2100, Copenhagen Ø, Denmark.
- Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Bräutigam, K., Skok, K., Szymonski, K., Rift, C. V., & Karamitopoulou, E. (2025). Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited – Exploring the “Space”. Cancer Letters, 622, 217699. https://doi.org/10.1016/j.canlet.2025.217699
Vancouver
Bräutigam K, Skok K, Szymonski K, Rift CV, Karamitopoulou E. Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited – Exploring the “Space”. Cancer Letters. 2025;622:217699. doi:10.1016/j.canlet.2025.217699
BibTeX
@article{Brutigam2025,
author = {Bräutigam, Konstantin and Skok, Kristijan and Szymonski, Krzysztof and Rift, Charlotte Vestrup and Karamitopoulou, Eva},
title = {Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited – Exploring the “Space”},
journal = {Cancer Letters},
year = {2025},
volume = {622},
pages = {217699},
doi = {10.1016/j.canlet.2025.217699}
}
EUVIMED